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Abstract
Endometrial cancer (EC) contributes substantially to total burden of cancer morbidity and mortality in the United States.
Family history is a known risk factor for EC, thus genetic factors may play a role in EC pathogenesis. Three previous genome-
wide association studies (GWAS) have found only one locus associated with EC, suggesting that common variants with large
effects may not contribute greatly to EC risk. Alternatively, we hypothesize that rare variants may contribute to EC risk. We
conducted an exome-wide association study (EXWAS) of EC using the Infinium HumanExome BeadChip in order to identify
rare variants associated with EC risk. We successfully genotyped 177,139 variants in a multiethnic population of 1,055 cases
and 1,778 controls from four studies that were part of the Epidemiology of Endometrial Cancer Consortium (E2C2). No
variants reached global significance in the study, suggesting that more power is needed to detect modest associations
between rare genetic variants and risk of EC.
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Introduction
Endometrial cancer (EC), a cancer of the uterine epithelial
lining that typically occurs near or after menopause, is the most
common cancer of the female reproductive organs and the 10th
leading cause of cancer death in women in the developed world
[1–3]. EC is strongly associated with estrogen-only post-meno-
pausal hormone therapy [4,5] and excess body weight [6] due to
increased aromatization of C-19 steroids by excess adipose tissue
[7]. These risk factors support the ‘‘unopposed estrogen’’
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hypothesis in which EC may develop because of the unchecked
mitogenic effects of estrogen in the absence of sufficient
progesterone [8]. Some studies have shown that family history
increases risk two to three-fold in younger women who have a first-
degree female relative with EC [9,10], while among older women
the association is less strong. In addition, there is an increased risk
of EC in women with Lynch syndrome [11], a hereditary
autosomal dominant condition that confers a high risk of
colorectal cancer as well. These observations suggest that germline
genetics may contribute to EC susceptibility.
Genome-wide association studies (GWAS) have successfully
identified more than a hundred susceptibility loci for a variety of
cancer types [12]. Three GWAS studies of EC have been
conducted to date with only one identifying a novel genome-wide
significant locus, rs4430796, (p = 7.1610210) associated with EC
[13] at the HNF1B gene region on chromosome 17q12. Two
independent studies subsequently replicated the association with
rs4450796 [14,15]. However, two other GWAS studies of EC
[14,16] were not able to identify additional genome-wide
significant loci, suggesting that common variants with large effects
may not highly contribute to the familial risk of EC.
Most risk alleles discovered through GWAS have modest effect
sizes that do not account for much heritability of common diseases
[17]. Moreover, GWAS studies have focused on common variants
(.5%) in the general population. Low frequency variants make up
a large fraction of genetic variation in humans and may explain a
substantial portion of the heritability in cancer etiology. Recent
exome-sequencing studies have found rare variants in candidate
susceptibility genes for familial colorectal cancer [18], breast
cancer [19], and prostate cancer [20], suggesting that analysis of
rare variants may also provide insight into the etiology of EC.
However, exome-sequencing studies require samples sizes that are
not amenable to large epidemiological studies due to the high cost
currently needed to achieve sufficient statistical power.
There has been a push to develop statistically powerful, yet
relatively inexpensive, methods to detect associations for rare
variants with larger effect sizes. Illumina has recently developed
the Infinium HumanExome BeadChip (exome array) from non-
synonymous variants found at least 3 times on more than 2 data
sets from the whole-exome sequencing of more than 12,000
individuals. This array provides a platform from which we can
begin to survey the landscape of rare variation in a large number
of samples.
We genotyped rare variants in a multiethnic population of 3,067
women (1,169 EC cases and 1,898 controls) from the Epidemi-
ology of Endometrial Cancer Consortium (E2C2) [21] in order to
test the hypothesis that rare variants in coding regions may be
associated with EC risk.
Methods
Ethics committee from each participating study (Alberta Health
Services; Estrogen, Diet, Genetics and Endometrial Cancer Study;
Multiethnic Cohort Study) obtained written informed consent
from all study participants. All written consent was approved from
the Institutional Review Board (IRB) from each institution
(Alberta Health Services, Canada; Memorial Sloan Kettering,
USA; University of Hawaii Cancer Center, USA; Keck School of
Medicine-University of Southern California, USA).
Alberta Health Services, Memorial Sloan Kettering, University
of Hawaii Cancer Center, and University of Southern California
institutional review boards specifically approved the present study
(Exome-Wide Association Study of Endometrial Cancer), as well
as the written consent obtained from participants.
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Participating studies also obtained IRB certification, permitting
data sharing according to the NIH Policy for Sharing of Data
Obtained in NIH Supported or Conducted Genome- Wide
Association studies (GWAS).
Study Population
Exome array genotyping was performed on 3,067 samples from
3 retrospective case-control studies: the Alberta Health Services
Study (AHS) [22], the Estrogen, Diet, Genetics and Endometrial
Cancer study (EDGE) [23], and the Fred Hutchinson Cancer
Research Center (FHCRC) study and 1 case-control study nested
within the prospective Multiethnic Cohort Study (MEC) [24].
Studies participating in this analysis are described in Table 1 and
in our previous GWAS[14]. Of the women included in the study,
1,169 were EC cases and 1,898 were controls. Cases were
restricted to those diagnosed with the most common subtype of EC
(type I) while controls were cancer free and had an intact uterus.
Controls were matched to cases by age and study site.
Genotyping and Quality Control
DNA was extracted at each study site from buffy coat or cheek-
cell samples following the manufacturer’s protocol and genotyped
at the University of Southern California using the Infinium
Human Exome BeadChip (Illumina Inc., San Diego, CA) as part
of the Stage II replication of the E2C2 GWAS. The BeadChip
included 9,232 custom markers, 2,211 of which are specifically
relevant to EC, in addition to the 247,870 markers coding
primarily for protein-altering variants already included in the
BeadChip’s default design.
Genotype calling was performed with Illumina GenCall on all
samples (n = 3,067) using the MEC cluster file (16,000
multiethnic samples) for the non-custom markers and autocluster-
ing for the custom markers. Variants were excluded from analyses
if call rates were , 90% (n = 115), the variant was monomorphic
(n = 77,521), the loci had no observed founders and missing all
genotypes (n = 1,962), the variant was an insertion or deletion
allele (n = 117), or the variant deviated from Hardy-Weinberg
equilibrium at p-value , 0.0001 in any ethnic group (n = 248).
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Figure 1. Minor allele frequency for all variants successfully
genotyped over all ethnicities. The number of variants is plotted by
the minor allele frequency over all ethnicities. These variants include
those that are monomorphic in all ethnicities.
doi:10.1371/journal.pone.0097045.g001
EXWAS Study of Endometrial Cancer
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The final disease trait analysis data set contained 177,139
successfully genotyped variants.
In total, 3,031 out of 3,067 samples were successfully genotyped
with call rates $ 90%. Of these, we removed 40 duplicate samples
(genotype concordance rate . 99.9%) used for assay quality
control and 15 samples for other quality control reasons. We
conducted principal components analysis (PCA) to identify self-
reported ethnicity outliers and infer ancestry with EIGENSOFT
v 4.2 [25] using 47,097 custom and non-custom SNPs with
genotyping rates . 90% and MAF . 1%. The HapMap phase II
(build 37) CEU, YRI, and JPT-CHB samples were used as
reference populations. Using the first 5 principal components, we
determined 7 individuals that were ethnicity outliers and excluded
them from analyses. After further removal of 136 outliers (more
than 3.5 standard deviations from the mean) of sample heterozy-
gosity by ethnicity, 2,833 women (1,055 EC cases and 1,778
controls) remained for disease trait analysis.
Statistical Analysis
Single variant association analysis. Single variant analyses
were performed overall and stratified by self-reported ethnic
group. For each SNP, we estimated odds ratios (OR) and 95%
confidence intervals (CI) using unconditional logistic regression,
assuming an additive genetic model (0, 1, 2 copies of the minor
allele) and adjusting for body mass index (BMI in kg/m2), age,
study site, plate, and the first 4 principal components to account
for population stratification. All single variant analyses were
performed using PLINK v 1.07 [26].
Gene-based analysis. As an additional method to discover
rare variants associated with EC, gene-based testing was
performed using SKAT-O [27] over all ethnicities. SKAT-O
combines gene-burden tests and SKAT, a SNPset level test for
association using kernel machine methods, in special cases for an
optimized approach that maximizes power. These analyses were
also adjusted for BMI, age, study site, plate and the first 4 principal
components. In total, 16,245 genes with at least one variant were
tested.
Statistical significance. We determined single variant asso-
ciation to reach global significance if the unadjusted p-value was
,2.82 6 1027, corresponding to a Bonferroni correction for
177,139 tests. Gene-based associations were considered significant
for unadjusted p-values ,3.08 6 1026, corresponding to a
Bonferroni correction for 16,245 tests.
In accordance to NIH/NCI policy all data will be submitted to
the database of Genotypes and Phenotypes (dbGaP, http://www.
ncbi.nlm.nih.gov/gap).
Results
Association analyses included 177,139 successfully genotyped
variants with MAF . 0 from a total of 257,102 variants included
in the array. Population characteristics of the four participating
studies (AHS, EDGE, FHCRC, and MEC) are described in
Table 1. Mean age at diagnosis for cases ranged from 58.5 years in
AHS to 65.5 years in MEC and mean BMI at diagnosis for cases
ranged from 28.8 kg/m2 in MEC to 32.3 kg/m2 in AHS and
EDGE. Of the 3,067 samples genotyped, 2,833 were included in
Figure 2. Minor allele frequency for all variants successfully genotyped by reported ethnicity. The number of variants is plotted by the
minor allele frequency for each ethnicity. All these variants are polymorphic in at least one reported ethnicity.
doi:10.1371/journal.pone.0097045.g002
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the analysis. There were no differences in age, BMI, and ethnicity
between excluded cases and those included in the analysis (results
not shown). Of these 2,833 individuals, there were 254 self-
reported African-Americans, 347 self-reported Asians, 1,686 self-
reported Caucasians, 79 self-reported Hawaiians, 360 self-reported
Latinas, and 107 who did not report a specific ethnicity (Table 2).
Variant Distribution among Reported Ethnicities
In this study population, 77,521 variants (30.4%) were found to
be monomorphic across all reported ethnicities and 177,139
variants (69.6%) were polymorphic in at least one ethnic
population with 74.0% of polymorphic alleles having MAF
# 1% (Figure 1). Of the variants that were polymorphic in at
least one ethnic population, 42.0% in African Americans, 71.7%
in Asians, 34.9% in Caucasians, 69.7% in Hawaiians, 49.5% in
Latinas, and 60.0% in those of unknown ethnicity were
monomorphic (Figure 2). The MAF distributions were fairly
similar among Asians, Hawaiians, and those who did not report a
specific ethnicity while African Americans, Caucasians, and
Latinas shared more similarities in MAF with each other than
with Asians, Hawaiians, and those of unknown ethnicity. About
20.2% (n = 35,912) of variants were shared by all 5 reported
ethnicities while Caucasians and Latinas had the most variants in
common at 41.1% (n = 72,878) (Figure 3). Caucasians had the
most unique polymorphic variants (18.7%), followed by African-
Americans (14.0%), Latinas (3.2%), Asians (2.7%), those who did
not report ethnicity (1.0%), and Hawaiians (0.4%).
Single Variant Association for Endometrial Cancer
No variants reached global significance in single variant
association of EC for all ethnicities combined (Figure 4a,
Table 3) when correcting for multiple comparisons using
the Bonferroni adjustment (p ,2.82 6 1027). The strongest
associations were for variants with .0.05 MAF (Table 3) located
within 50 kb of the long non-protein coding intergenic RNA,
LINC00520 (rs1953358, OR = 1.36, p = 4.7661027) and in the
intron region of PROS1 (rs8178648, OR = 1.71, p = 1.53 6
1026), which codes for protein S, a cofactor to protein C in the
anti-coagulation pathway. In Caucasians, who make up the
majority of the overall analysis, only rs8178648 remained
suggestively associated with OR = 1.98 and p = 3.35 6 1026
(Figure 4b, Table 3). There were no globally significant or
suggestive variants in African Americans, Asians, Hawaiians,
Latinas, and those who did not report ethnicity (Table S1).
Gene-based Analysis of Endometrial Cancer
None of the gene-based tests of association were globally
significant (p , 3.08 6 1026) after adjusting for multiple
comparisons (Table S2). Of the 16,245 genes tested, the most
significant EC association was with KRT81 (p = 2.216 1025), a
member of the keratin gene family located on 12q13. PROS1,
where rs8178648 is located, was not significantly associated with
EC (p = 0.6789) when testing over all ethnicities neither when
testing only in Causasians (results not shown).
Figure 3. Six-way Venn diagram showing polymorphic putative functional variants shared by reported ethnicities. Numbers of shared
variants are shown at intersections. The total numbers of polymorphic variants by ethnicity are listed in the upper-left hand corner.
doi:10.1371/journal.pone.0097045.g003
EXWAS Study of Endometrial Cancer
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Figure 4. Manhattan plots for the endometrial cancer association analysis. Results of single variant analyses (2log10p) are plotted against
chromosome position (NCBI build 37) for association over all ethnicities (A) and for associations within Caucasians (B). Suggestive variants are labeled
above. Results were adjusted for age at diagnosis, BMI, study site, plate, and the first four principal components.
doi:10.1371/journal.pone.0097045.g004
EXWAS Study of Endometrial Cancer
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Discussion
We present an initial exploration into whether rare variants are
associated with EC risk in a multiethnic population from the
E2C2. No variants reached global significance (p , 2.8261027)
in the single variant association analyses of EC in all ethnicities
combined or when stratified by reported ethnicity. Additionally,
no gene-based test of association reached global significance
(p , 3.086 1026).
Among all ethnicities, rs8178648 on chromosome 3 maintained
a suggestive association with EC (OR = 1.707, 95% CI: 1.363–
2.123, p = 1.5361026). The variant lies within the intron region
of PROS1, a gene coding for protein S, a cofactor in the
anticoagulant pathway that causes autosomal dominant hereditary
thrombophilia when mutated [28]. PROS1 expression has been
reported to be elevated in aggressive prostate cancer tissue [29]
and thyroid cancer tissue [30], suggesting it may have a role in
cancer etiology or progression. PROS1 has been found to be
directly upregulated by progestins [31] and downregulated by
17b-Estradiol, an estrogen that regulates gene expression via the
estrogen receptor [32], making it susceptible to imbalances in the
sex hormone metabolic pathway, which is implicated in EC
etiology. However, PROS1 was not significantly associated with
EC (p= 0.6789) when using SKAT-O and no other GWAS have
found significant or suggestive variants in this gene.
One weakness of this study is our limited sample size, which was
not sufficiently powered to detect rare variants with modest effects
associated with EC. Additionally, the exome array content is
predominantly based on European ancestry whereas our study
included a substantial number of samples with other ancestries.
Incomplete exome array coverage of all functional variants and
indels that may impact EC risk may also have limited the scope of
our study. However, our analysis is one of only two studies [33]
using the exome array to examine associations between rare
variants and complex diseases in large multiethnic populations.
Our study is also the first to utilize the exome array with EC and
serves as an extension to our previous examination of common
variants on EC risk.
A previous GWAS [13] identified one novel locus near HNF1B,
rs4430796, inversely associated with EC risk. We replicated the
findings in our GWAS [14], but no other common variants
associated with EC have been determined. Exome arrays that
focus on rare variants, which are hypothesized to have larger effect
sizes than common variants, have been used to successfully identify
new loci influencing insulin processing and secretion in type 2
diabetics [34]. To date, analyses of cancer sites using exome arrays
have failed to find strong evidence that rare variants are highly
associated with cancer, revealing only one variant significantly
associated with breast cancer and none with prostate cancer [33].
Similarly, we have not identified any loci significantly associated
with EC. Due to our limited sample size, our study was estimated
to be sufficiently powered to detect ORs . 2.53 for low frequency
variants (MAF=0.02). An OR of 2.00 (MAF=0.01) would also
need around 4,250 cases and 7,250 controls to be sufficiently
powered. Even for variants with higher MAFs similar to what was
observed for rs8178648, a study detecting a per-allele OR of 1.70
would require at least 1,107 cases and 1,871 controls to be
considered sufficiently powered (b=0.80). Therefore, larger
studies need to be conducted in order to detect novel associations
with rare variants.
In conclusion, our study found no evidence that rare variants
with large effect sizes are associated with EC risk. Though we were
able to identify a few suggestive associations, as with rs8178648,
much larger studies would be needed to identify a more modest
influence of rare variants on the risk of EC.
Supporting Information
Table S1 1–5. Single variant association results. Top 100
most significant single variant associations with endometrial cancer
by ethnic groups.
(XLSX)
Table S2 SKAT-O gene based association results.
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